Source - SMW
Futura Medical said a clinical trial of its erectile dysfunction treatment had not met its primary goals versus a placebo.    The treatment, FM57, was compared to Futura's proprietary transdermal DermaSys formulation in the so-called phase three trial.
 
At 10:05am: (LON:FUM) Futura Medical PLC share price was -18.95p at 10.05p



Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.